Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
MannKind Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
MannKind Corp, Medical Devices Deals, 2011 to YTD 2017 10
MannKind Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
MannKind Corp, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
MannKind and Biomm Enter into Distribution Agreement 12
MannKind Partners with JDRF 13
Licensing Agreements 14
Receptor Life Sciences Enters into Licensing Agreement with MannKind 14
Colby Enters Into Licensing Agreement With MannKind For Cancer Immunotherapy Products 15
MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton’s Tyrosine Kinase Inhibitors 17
Equity Offering 18
Mannkind to Raise USD61 Million in Private Placement of Shares 18
MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 20
MannKind Raises USD36.2 Million in Private Placement of Shares 21
Mannkind Raises USD50 Million in Private Placment of Shares 22
MannKind Announces Public Offering Of Common Stock For US$50 Million 24
MannKind Completes Public Offering Of Common Stock And Warrants For US$92 Million 25
MannKind Completes Public Offering Of Units For US$86 Million 27
Debt Offering 29
MannKind Completes First Tranche Of Private Placement Of Notes For US$40 Million 29
MannKind Plans Public Offering Of Senior Secured Discount Notes Due 2017 For US$370 Million 31
MannKind Corp – Key Competitors 32
MannKind Corp – Key Employees 33
MannKind Corp – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Nov 07, 2017: MannKind Reports 2017 Third Quarter Financial Results 35
Aug 07, 2017: MannKind Reports 2017 Second Quarter Financial Results 37
May 10, 2017: MannKind Reports 2017 First Quarter Financial Results 39
Mar 16, 2017: MannKind Reports 2016 Fourth Quarter and Full Year Financial Results 40
Nov 09, 2016: MannKind Reports 2016 Third Quarter Financial Results 42
Aug 08, 2016: MannKind Reports 2016 Second Quarter Financial Results 44
May 09, 2016: MannKind Reports 2016 First Quarter Financial Results 45
Mar 14, 2016: MannKind Reports 2015 Fourth Quarter and Full Year Financial Results 46
Corporate Communications 47
Jul 17, 2017: Steven Binder Joins MannKind as Chief Financial Officer 47
Jul 12, 2017: Patrick McCauley Joins MannKind as Chief Commercial Officer 48
Jan 04, 2017: MannKind Announces Key Addition to Its Executive Management Ranks 49
Feb 19, 2016: Alfred Mann Steps Down as Executive Chairman of Mannkind 50
Jan 11, 2016: MannKind Provides Update on Senior Management 51
Product News 52
08/01/2016: Mannkind Assumes Responsibility for Distribution of Afrezza and Launches Patient Reimbursement and Adherence Support Programs 52
06/12/2016: MannKind Announces Late-Breaking Data Demonstrating Faster Onset and Shorter Duration of Action Compared to Mealtime Insulins 53
Mar 08, 2017: MannKind and Charles Mattocks Announce “REVERSED”-America’s First Docu-Series Tackling Diabetes 55
02/01/2017: MannKind Announces Launch of New Titration Pack and Field Force Expansion to Accelerate Afrezza Growth 56
Other Significant Developments 57
Jan 09, 2017: MannKind Receives $30.6 Million From Sanofi 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58
MannKind Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
MannKind Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
MannKind Corp, Deals By Therapy Area, 2011 to YTD 2017 9
MannKind Corp, Medical Devices Deals, 2011 to YTD 2017 10
MannKind Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
MannKind and Biomm Enter into Distribution Agreement 12
MannKind Partners with JDRF 13
Receptor Life Sciences Enters into Licensing Agreement with MannKind 14
Colby Enters Into Licensing Agreement With MannKind For Cancer Immunotherapy Products 15
MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton’s Tyrosine Kinase Inhibitors 17
Mannkind to Raise USD61 Million in Private Placement of Shares 18
MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 20
MannKind Raises USD36.2 Million in Private Placement of Shares 21
Mannkind Raises USD50 Million in Private Placment of Shares 22
MannKind Announces Public Offering Of Common Stock For US$50 Million 24
MannKind Completes Public Offering Of Common Stock And Warrants For US$92 Million 25
MannKind Completes Public Offering Of Units For US$86 Million 27
MannKind Completes First Tranche Of Private Placement Of Notes For US$40 Million 29
MannKind Plans Public Offering Of Senior Secured Discount Notes Due 2017 For US$370 Million 31
MannKind Corp, Key Competitors 32
MannKind Corp, Key Employees 33
MannKind Corp, Other Locations 34